Clinical Trials Logo
  1. Home
  2. Ischemic Stroke
  3. NCT04971564
  4. Details
NCT04971564 Clinical Trial

Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia

Ischemic Stroke Clinical Trial

— RADICAL  

Official title:
Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. A Case-control Trial Nested in a Cohort

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04971564
Other study ID # FDE_2021_19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 19, 2024
Est. completion date June 22, 2026

Study information
Verified date June 2024
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact François DELVOYE
Phone 0148036556
Email fdelvoye@for.paris
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date June 22, 2026
Est. primary completion date June 22, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admitted to the Rothschild Foundation within the first 24 hours of an acute neurological symptomatology related to : - ischemic stroke eligible for a mechanical thrombectomy procedure - subarachnoid haemorrhage due to aneurysmal rupture: patient with at least a modified Fisher scale 3 or 4 (Appendix 4) and a World Federation of Neurological Surgeons (WFNS) score of 2 or more - intra-parenchymal haematoma with a Glasgow Coma Scale (GCS) strictly below 15. - tissue-based transient ischaemic attack - no lesion found on imaging - with ABCD2= 2 (control group). - Hospitalisation to the Fondation Adolphe de Rothschild Hospital at least 72 hours is planned Exclusion Criteria: - Pre-existing functional and/or cognitive disability - Patient under legal protection - Pregnant or breastfeeding woman

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Blood sampling
Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion

Locations
Country Name City State
France Hôpital Fondation Adolphe de Rothschild Paris Ile-de-France

Sponsors (1)
Lead Sponsor Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Biomarker rates at day 0 Biomarker: Neutro-Plaket aggregates, extra-cellular DNA networks, von Willebrand Factor 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2